Catch up on the essentials
- Pfizer’s raised 2026 guidance indicates that growth outside its COVID franchise is beginning to offset pressure from mature products, although the company’s broader post-2028 growth case remains unproven by the reported results.
- Excluding Comirnaty and Paxlovid, revenue grew 7% operationally, while launched and acquired products grew 32%.
- The company also began a next phase expected to add $2.5 billion in net cost savings from 2027 to 2029.
Selected from this article · 2026-11-06
Read on for the full picturePfizer’s raised 2026 guidance indicates that growth outside its COVID franchise is beginning to offset pressure from mature products, although the company’s broader post-2028 growth case remains unproven by the reported results.
The drugmaker reported third-quarter 2026 revenue of $16.6 billion, essentially flat year over year on an operational basis. Reported diluted EPS was $0.56, while adjusted diluted EPS was $0.87 and unchanged from a year earlier. Pfizer raised full-year revenue guidance by $1.5 billion at the midpoint to $62.0 billion-$64.0 billion and raised and narrowed adjusted diluted EPS guidance to $2.95-$3.05 from $2.80-$3.00.
Non-COVID products offset franchise declines
Excluding Comirnaty and Paxlovid, revenue grew 7% operationally, while launched and acquired products grew 32%. The disclosed growth mix was led by Eliquis, Padcev, the Vyndaqel family, Nurtec ODT/Vydura and Lorbrena, which contributed operational increases of $513 million, $255 million, $193 million, $135 million and $114 million, respectively.
Those gains were offset by operational declines of $771 million for Paxlovid, $339 million for Comirnaty and $180 million for the Prevnar family. The comparison therefore supports a narrow conclusion: Pfizer’s non-COVID portfolio is currently carrying more of the company’s growth, but the reviewed disclosures do not establish how durable that contribution will be after the current product mix and patent expirations take effect.
The guidance raise absorbs a one-time charge
Pfizer’s raised guidance includes a one-time $650 million Acquired In-Process R&D charge related to the Innovent Biologics in-licensing agreement recorded in the third quarter. Another report said the transaction charge reduced adjusted diluted EPS by $0.10.
The charge makes the adjusted earnings comparison less straightforward. Pfizer nevertheless reported a 36% adjusted operating margin for the quarter and raised adjusted diluted EPS guidance despite the charge. Reported net income was $3.2 billion, down 8% from $3.5 billion a year earlier, illustrating the difference between reported profit and the adjusted earnings measure used in guidance.
Cost savings support the near-term outlook
Interim CFO Cecile Guegan said Pfizer remained on track to deliver nearly all of an anticipated $7.2 billion in net savings by the end of 2026. The company also began a next phase expected to add $2.5 billion in net cost savings from 2027 to 2029.
This is a company expectation rather than a realized result. It nevertheless provides a potential earnings bridge that is distinct from product revenue: the near-term guidance raise is supported by growth in launched and acquired products, while cost reduction is expected to provide an additional contribution.
Pipeline and portfolio signals
Pfizer reported recent pipeline progress, including eight pivotal study starts, one pivotal readout and two regulatory decisions. The disclosures included FDA approvals for Talzenna in prostate cancer and Tukysa in HER2-positive breast cancer. Chief Scientific Officer Chris Boshoff also said Elrexfio monotherapy produced a statistically significant and clinically meaningful improvement in progression-free survival versus investigator’s choice in MM-32, with more than 75% of patients free of disease progression or death at the interim analysis.
These developments support Pfizer’s broader pipeline narrative, but the reviewed reports do not establish a new procurement process, customer order or near-term revenue contribution from them.
The next observable test is whether Pfizer can sustain operational growth outside COVID while absorbing the Innovent charge and delivering its expected savings. The company also expects approximately $4 billion in COVID-product revenue for 2026, with most Comirnaty revenue expected in the fourth quarter, making fourth-quarter execution relevant to the raised range.
Industry and product implications
Industry / product | Disclosed fact | Demand interpretation | Verification signal | Main risk |
|---|---|---|---|---|
Eliquis | Eliquis revenue increased $513 million operationally and was identified as a primary driver of third-quarter growth. [1] | Disclosed fact; operating. Operational revenue growth from an existing commercial product. | Whether Eliquis continues contributing operational growth in Pfizer's subsequent disclosures. | Reported growth does not establish durability after future patent expirations. |
Padcev | Padcev revenue increased $255 million operationally and was identified as a primary driver of third-quarter growth. [1] | Disclosed fact; operating. Operational revenue growth from an existing commercial oncology product. | Whether Padcev continues contributing operational growth in Pfizer's subsequent disclosures. | One quarter's growth does not establish sustained demand. |
Vyndaqel family | The Vyndaqel family recorded a $193 million operational revenue increase and was identified as a primary growth driver. [1] | Disclosed fact; operating. Operational revenue growth from an existing commercial product family. | Whether the product family continues contributing operational growth in Pfizer's subsequent disclosures. | Reported growth does not establish durability after future patent expirations. |
Nurtec ODT/Vydura | Nurtec ODT/Vydura recorded a $135 million operational revenue increase and was identified as a primary growth driver. [1] | Disclosed fact; operating. Operational revenue growth from an existing commercial product franchise. | Whether Nurtec ODT/Vydura continues contributing operational growth in Pfizer's subsequent disclosures. | The combined disclosure does not provide a product-level breakdown. |
Lorbrena | Lorbrena recorded a $114 million operational revenue increase and was identified as a primary growth driver. [1] | Disclosed fact; operating. Operational revenue growth from an existing commercial oncology product. | Whether Lorbrena continues contributing operational growth in Pfizer's subsequent disclosures. | One quarter's growth does not establish sustained demand. |
Elrexfio monotherapy | Chris Boshoff said Elrexfio monotherapy showed a statistically significant and clinically meaningful improvement in progression-free survival versus investigator's choice in MM-32. [3] | Disclosed fact; operating. Reported progression-free-survival improvement in a named clinical study. | Subsequent regulatory, clinical and commercial disclosures for Elrexfio monotherapy. | The reported interim analysis does not establish approval, reimbursement, procurement or revenue contribution. |
Share this article
